Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2100 of 2529 entries
View as:

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

Phase: N/A Priority: Normal
NCT ID: NCT04156620 Org: User:
Start: 12/11/19 End: 12/20/22 Due: 12/20/23

A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia

Phase: N/A Priority: Normal
NCT ID: NCT04943497 Org: User:
Start: 07/27/21 End: 06/30/25 Due: 06/30/26

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Phase: N/A Priority: Normal
NCT ID: NCT02414139 Org: User:
Start: 06/11/15 End: 05/16/23 Due: 05/16/24

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01433445 Org: User:
Start: 11/01/11 End: 06/22/20 Due: 06/22/21

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00434148 Org: User:
Start: 12/31/06 End: 05/31/14 Due: 05/31/15

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

Phase: N/A Priority: Normal
NCT ID: NCT01482143 Org: User:
Start: 03/31/12 End: 10/31/13 Due: 10/31/14

Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)

Phase: N/A Priority: Normal
NCT ID: NCT00116376 Org: User:
Start: 01/31/04 End: 11/30/05 Due: 11/30/06

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05108740 Org: User:
Start: - End: - Due: -

Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials

Phase: N/A Priority: Normal
NCT ID: NCT05301907 Org: User:
Start: 12/02/21 End: 05/30/25 Due: 05/30/26

Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria

Phase: N/A Priority: Normal
NCT ID: NCT04300309 Org: User:
Start: 12/21/20 End: 05/10/24 Due: 05/10/25

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04427072 Org: User:
Start: 09/25/20 End: 11/06/23 Due: 11/06/24

Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation

Phase: N/A Priority: Normal
NCT ID: NCT03334812 Org: User:
Start: 10/18/17 End: 04/05/19 Due: 04/05/20

COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT03917459 Org: User:
Start: 04/16/19 End: 05/25/21 Due: 05/25/22

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Phase: N/A Priority: Normal
NCT ID: NCT04878211 Org: User:
Start: 06/10/21 End: 04/14/23 Due: 04/14/24

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02152761 Org: User:
Start: 09/16/14 End: 10/25/18 Due: 10/25/19

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Phase: N/A Priority: Normal
NCT ID: NCT02292446 Org: User:
Start: 11/21/14 End: 12/29/17 Due: 12/29/18

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Phase: N/A Priority: Normal
NCT ID: NCT03785405 Org: User:
Start: 05/02/19 End: 12/29/23 Due: 12/29/24

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

Phase: N/A Priority: Normal
NCT ID: NCT03781414 Org: User:
Start: 10/07/19 End: 04/20/23 Due: 04/20/24

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Phase: N/A Priority: Normal
NCT ID: NCT04181762 Org: User:
Start: 07/07/20 End: 09/13/23 Due: 09/13/24

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Phase: N/A Priority: Normal
NCT ID: NCT01059318 Org: User:
Start: 01/31/10 End: 06/30/12 Due: 06/30/13

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

Phase: N/A Priority: Normal
NCT ID: NCT04072887 Org: User:
Start: 09/12/19 End: 02/01/22 Due: 02/01/23

Pediatric Epilepsy Study

Phase: N/A Priority: Normal
NCT ID: NCT00050947 Org: User:
Start: 07/31/02 End: 02/29/04 Due: 02/28/05

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT01640951 Org: User:
Start: 09/16/12 End: 05/04/17 Due: 05/04/18

Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00909324 Org: User:
Start: 08/01/09 End: 01/01/10 Due: 01/01/11

Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05982886 Org: User:
Start: 01/15/21 End: 04/01/21 Due: 04/01/22